Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan

References

• Naish J. Medical sciences. London, UK: Elsevier Health Sciences; 2014.
   Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. J Clin Appl Res Educ. 2016;39.
   Google Scholar
• Ram CV. Fixed-dose triple-combination treatments in the management of hypertension. Manag Care. 2013;22(12):45–55.
   PubMedGoogle Scholar
• Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: a review of the evidence. Am J Health Syst Pharm. 2010;67(11):885–894.
   PubMed Web of Science ®Google Scholar
• Patel A, Group AC. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
   PubMed Web of Science ®Google Scholar
• Gradman AH. Rationale for triple‐combination therapy for management of high blood pressure. J Clin Hypertens. 2010;12(11):869–878.
   PubMed Web of Science ®Google Scholar
• Brixner DI, Jackson IIKC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations*. Curr Med Res Opin® 2008, 24(9):2597–2607. **
   PubMed Web of Science ®Google Scholar
• Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065–2076. **
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035. **.
   PubMed Web of Science ®Google Scholar
• Hyre AD, Krousel‐Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens. 2007;9(3):179–186.
   Google Scholar
• Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–1117.
   PubMed Web of Science ®Google Scholar
• Gallagher BD, Muntner P, Moise N, et al. Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? J Hypertens. 2015;33(5):1108–1113.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen H, Essien E, et al. Medication adherence to antihypertensive triple-combination therapy among patients enrolled in a medicare advantage plan. J Manag Care Spec Pharm. 2019;25(6):678–686. **.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, et al. American society of hypertension writing G: combination therapy in hypertension. J Am Soci Hypertens. 2010;4(1):42–50.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730–740.
   PubMed Web of Science ®Google Scholar
• Sherrill B, Halpern M, Khan S, et al. Single‐pill vs free‐equivalent combination therapies for hypertension: a meta‐analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898–909. **.
   Web of Science ®Google Scholar
• Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21(5):509–513.
   PubMed Web of Science ®Google Scholar
• Malesker MA, Hilleman DE. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Managed Care (Langhorne, Pa). 2010;19(7):36–42.
   PubMedGoogle Scholar
• Hilleman DE. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. J Managed Care Pharm. 2014;20(1):93–100.
   Google Scholar
• Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed‐dose amlodipine besylate/benazepril HCl versus comparable component‐based therapy. Congest Heart Fail. 2003;9(6):324–332.
   PubMedGoogle Scholar
• Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly. Am J Cardiovasc Drugs. 2008;8(1):45–50.
   PubMed Web of Science ®Google Scholar
• Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis. 2007;18(2):204–209.
   Web of Science ®Google Scholar
• Saito I, Kobayashi M, Matsushita Y, et al. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res. 2008;31(7):1373–1383.
   PubMed Web of Science ®Google Scholar
• Stafylas P, Kourlaba G, Hatzikou M, et al. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Eff Resour Allocation. 2015;13(1):10.
   PubMedGoogle Scholar
• Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10(6):498–509.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen H, Essien EJ, et al. Risk of cardiovascular outcomes and antihypertensive triple combination therapy among elderly patients with hypertension enrolled in a medicare advantage plan (MAP). Am J Cardiovasc Drugs. 2020. DOI:10.1007/s40256-020-00395-0
   Web of Science ®Google Scholar
• Martin C, Vanderpump M, French J. Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors. BMC Med Inform Decis Mak. 2004;4(1):6. *. .
   PubMedGoogle Scholar
• Leslie SR, Gwadry-Sridhar F, Thiebaud P, et al. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharm Prog. 2008;1(1):13–19.
   Google Scholar
• Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Jan]. https://www.rxpricequotes.com/.
   Google Scholar
• [cited 2017 Jan]. https://www.goodrx.com/.
   Google Scholar
• Olga KD, Phelps, Alyssa, et al.. Projections of cardiovascular disease prevalence and costs: 2015–2035; 2016.
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Cost-effectiveness in health and medicine. New York: Oxford University; 1996. p. 55.
   Google Scholar
• [cited 2017 Jan]. http://healtheconomics.tuftsmedicalcenter.org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspx.
   Google Scholar
• Chowdhury EK, Ademi Z, Moss JR, et al. Cost–utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity. Medicine (Baltimore). 2015;94(9). DOI:10.1097/MD.0000000000000590
   Web of Science ®Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397–401.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1):293–298. *.
   PubMed Web of Science ®Google Scholar
• Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Internal Med. 1999;159(11):1197–1204.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation. 2008;117(6):743–753.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25(1):40–43.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2):272–281.
   PubMed Web of Science ®Google Scholar
• Bolooki HM, Askari A. Acute myocardial infarction. Disease Manag Proj. 2010.
   Google Scholar
• Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38(1):46–51.
   PubMed Web of Science ®Google Scholar
• Yang Q. Vital Signs: recent Trends in Stroke Death Rates—United States, 2000–2015. MMWR Morb Mortal Wkly Rep. 2017;66. doi:10.15585/mmwr.mm6635e1
   Web of Science ®Google Scholar
• Cobden DS, Niessen LW, Rutten FFH, et al. Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. Patient Prefer Adherence. 2010;4:283.
   PubMed Web of Science ®Google Scholar
• Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1984;5(2):157–177.
   Google Scholar
• Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non‐parametric bootstrap. Stat Med. 2000;19(23):3219–3236.
   PubMed Web of Science ®Google Scholar
• Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost‐effectiveness acceptability curves. Health Econ. 2000;9(7):623–630.
   PubMed Web of Science ®Google Scholar
• You JHS. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation—a cost-effectiveness analysis. J Gen Intern Med. 2014;29(3):438–446.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Park J-H, Lee Y-H, Ko S-K, et al. Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+ atorvastatin). Epidemiol Health. 2015;37.
   Web of Science ®Google Scholar
• Klarenbach SW, McAlister FA, Johansen H, et al. Canadian hypertension education P: identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension. Can J Cardiol. 2010;26(5):e158–e163.
   PubMedGoogle Scholar